Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Score, Valuation & Financial Research

Liminatus Pharma, Inc. Class A Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for LIMN

Liminatus Pharma, Inc. Class A Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 3.70. These figures are a research snapshot, not a buy or sell recommendation.

What Liminatus Pharma, Inc. Class A Common Stock does

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Liminatus Pharma, Inc. is a pre-clinical stage biopharmaceutical company that does not currently generate revenue from product sales. The company focuses on developing novel cancer therapies, specifically monoclonal antibodies, and relies on external financing to fund its research, development, and operational activities.

Products and services

  • The company's lead clinical candidate is IBA101, a humanized anti-CD47 monoclonal antibody designed to block the CD47 'do not eat me' signal on cancer cells to restore immune-cell phagocytosis.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for drug substance and finished product; specific supplier names are unnamed. Source

Business relationships and partnerships

  • InnoBation Bio Co. Ltd. — The company licenses its CD47 asset from InnoBation Bio Co. Ltd. Source

Business strengths to evaluate

  • Development of novel cancer therapies targeting the CD47 immune checkpoint Source

Business risks and research considerations

  • Pre-clinical stage status with no history of revenue and significant accumulated deficits Source
  • Dependence on third-party contract manufacturers for production Source
  • Nasdaq listing deficiency risks related to market value and minimum bid price Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

LIMN financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.70
Market capitalization:
4.97M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -12.52M
Free cash flow:
USD -9.98M
Cash:
USD 3.02M
Total debt:
USD 1.44M
EPS:
USD -23.70

What stands out

  • Free cash flow is USD -9.98M, negative for the stored period.
  • The balance sheet shows USD 3.02M of cash versus USD 1.44M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 1.57M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for LIMN

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can LIMN fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is LIMN likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for LIMN to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of LIMN's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research LIMN

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.